Suneva Medical and Viveon Health Acquisition Corp, a special purpose acquisition company (SPAC), have entered into a definitive merger agreement to create a regenerative aesthetics company. Upon completion of the transaction, the combined company’s securities are expected to be traded on the NYSE under the symbol “RNEW.”
Suneva’s portfolio of products include Bellafill, FDA-approved for correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheeks; Silhouette Instalift, the first resorbable suture FDA-cleared for cosmetic facial procedures; PlasmaIQ, a hand-held FDA-cleared plasma energy device for skin rejuvenation; Puregraft fat grafting system; Dermapose, an all-in-one system to harvest, wash and inject fat; and Amplifine, a high-density platelet rich plasma (PRP) gel tube and syringe technology.
Pat Altavilla, CEO of Suneva Medical, will lead the combined company. Jagi Gill, CEO and chairman of Viveon Health, will join the Board of Directors of Suneva Medical.
“We are excited to be partnering with Viveon Health as we step into the next phase of growth as a leader in the regenerative aesthetics sector supporting the needs of physicians and patients seeking proven and validated innovations,” said Altavilla. “Our journey to this point has been paved with product innovation and clinical education led by an experienced team that brings a proven track record of sales growth and market development.”
